ACADIA Pharmaceuticals Inc. (ACAD) financial statements and ratios from SEC XBRL: revenue $1.1B (TTM), net margin 36.5%, revenue growth 9.7% YoY, P/E 13.4. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $1.07B |
| Revenue (TTM) | $1.1B |
| Net Margin | 36.5% |
| Operating Margin (TTM) | 7.4% |
| Revenue Growth (YoY) | 9.7% |
| EPS Growth (YoY) | -81.8% |
| FCF Growth (YoY) | 41.6% |
| P/E Ratio | 13.4 |
| EV / EBITDA | 58.3 |
| Price / Book | 4.05 |
| Price / Sales | 4.61 |
| FCF Yield | 2.3% |
| Altman Z-Score | 8.85 (safe) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
ACAD overview · ACAD earnings · ACAD KPIs · ACAD documents · ACAD ownership · ACAD peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.